Plasma Tie2 trajectories identify vascular response criteria for VEGF inhibitors across advanced biliary tract, colorectal and ovarian cancers

[1]  A. Gadducci,et al.  Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial. , 2021, The Lancet. Oncology.

[2]  Yulei N. Wang,et al.  Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. , 2020, The New England journal of medicine.

[3]  F. Marmé,et al.  Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer. , 2019, The New England journal of medicine.

[4]  M. Birrer,et al.  Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial. , 2019, The Lancet. Oncology.

[5]  E. Schmidt,et al.  Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial. , 2019, The Lancet. Oncology.

[6]  G. Parker,et al.  Plasma Tie2 is a tumor vascular response biomarker for VEGF inhibitors in metastatic colorectal cancer , 2018, Nature Communications.

[7]  D. Cunningham,et al.  Circulating biomarkers during treatment in patients with advanced biliary tract cancer receiving cediranib in the UK ABC-03 trial , 2018, British Journal of Cancer.

[8]  P. Ram,et al.  Macrophages Facilitate Resistance to Anti-VEGF Therapy by Altered VEGFR Expression , 2017, Clinical Cancer Research.

[9]  K. Baggerly,et al.  Macrophage depletion through colony stimulating factor 1 receptor pathway blockade overcomes adaptive resistance to anti-VEGF therapy , 2017, Oncotarget.

[10]  Gordon C Jayson,et al.  Antiangiogenic therapy in oncology: current status and future directions , 2016, The Lancet.

[11]  G. Jayson,et al.  Systematic analysis of circulating soluble angiogenesis-associated proteins in ICON7 identifies Tie2 as a biomarker of vascular progression on bevacizumab , 2016, British Journal of Cancer.

[12]  D. Cunningham,et al.  Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial , 2015, The Lancet. Oncology.

[13]  R. Greil,et al.  Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. , 2013, The Lancet. Oncology.

[14]  L. Naldini,et al.  Targeting the ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells. , 2011, Cancer cell.

[15]  G. Jayson,et al.  'Fit-for-purpose' validation of SearchLight multiplex ELISAs of angiogenesis for clinical trial use. , 2009, Journal of immunological methods.

[16]  Kevin Camphausen,et al.  Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Douglas G Altman,et al.  REporting recommendations for tumour MARKer prognostic studies (REMARK). , 2005, European journal of cancer.